These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 16144036

  • 1. Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses.
    Estcourt MJ, Létourneau S, McMichael AJ, Hanke T.
    Eur J Immunol; 2005 Sep; 35(9):2532-40. PubMed ID: 16144036
    [Abstract] [Full Text] [Related]

  • 2. Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help.
    Estcourt MJ, McMichael AJ, Hanke T.
    Eur J Immunol; 2005 Dec; 35(12):3460-7. PubMed ID: 16245361
    [Abstract] [Full Text] [Related]

  • 3. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE, Abaitua F, Rodríguez D, Esteban M.
    Virus Res; 2004 Sep 15; 105(1):11-22. PubMed ID: 15325077
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
    Li W, Li S, Hu Y, Tang B, Cui L, He W.
    Vaccine; 2008 Jun 19; 26(26):3282-90. PubMed ID: 18472194
    [Abstract] [Full Text] [Related]

  • 7. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
    Wang X, Uto T, Akagi T, Akashi M, Baba M.
    J Virol; 2007 Sep 19; 81(18):10009-16. PubMed ID: 17609261
    [Abstract] [Full Text] [Related]

  • 8. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J, Ngai N, Stone GW, Yue FY, Ostrowski MA.
    Vaccine; 2009 Aug 13; 27(37):5077-84. PubMed ID: 19573639
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine.
    Calarota SA, Weiner DB, Lori F, Lisziewicz J.
    Vaccine; 2007 Apr 20; 25(16):3070-4. PubMed ID: 17292518
    [Abstract] [Full Text] [Related]

  • 11. Genital CD8+ T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus.
    de Souza AP, Haut LH, Silva R, Ferreira SI, Zanetti CR, Ertl HC, Pinto AR.
    Vaccine; 2007 Jan 02; 25(1):109-16. PubMed ID: 16914235
    [Abstract] [Full Text] [Related]

  • 12. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG, Xu JQ, Ren L, Qiu C, Zhang N, Liu LX, Wan YM, Peng H, Shao YM.
    Zhonghua Yi Xue Za Zhi; 2006 Nov 28; 86(44):3109-13. PubMed ID: 17313761
    [Abstract] [Full Text] [Related]

  • 13. Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines.
    Steers NJ, Peachman KK, McClain S, Alving CR, Rao M.
    Vaccine; 2009 Nov 16; 27(49):6939-49. PubMed ID: 19748578
    [Abstract] [Full Text] [Related]

  • 14. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
    Hovav AH, Cayabyab MJ, Panas MW, Santra S, Greenland J, Geiben R, Haynes BF, Jacobs WR, Letvin NL.
    J Virol; 2007 Jan 16; 81(1):74-83. PubMed ID: 17050608
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Neonatal CD8+ T cells are slow to develop into lytic effectors after HSV infection in vivo.
    Fernandez MA, Evans IA, Hassan EH, Carbone FR, Jones CA.
    Eur J Immunol; 2008 Jan 16; 38(1):102-13. PubMed ID: 18081035
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Novel vaccines against M. tuberculosis].
    Okada M.
    Kekkaku; 2006 Dec 16; 81(12):745-51. PubMed ID: 17240920
    [Abstract] [Full Text] [Related]

  • 19. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
    Kumar S, Aggarwal P, Vajpayee M, Pandey RM, Seth P.
    Vaccine; 2006 Mar 24; 24(14):2585-93. PubMed ID: 16480792
    [Abstract] [Full Text] [Related]

  • 20. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W, Ren L, Jin N.
    J Virol Methods; 2007 Dec 24; 146(1-2):266-73. PubMed ID: 17868910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.